Monograph Details
|
|
Neoplasms
> Retinoids
|
|
PANRETIN |
| Manufacturer |
|
Eisai Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Retinoid. |
| Generic Name |
|
Alitretinoin 0.1%; gel. |
| Indications |
|
Cutaneous lesions of AIDS-related Kaposi's sarcoma (KS). |
| Children |
|
Not recommended. |
| Adults |
|
Apply twice daily to lesions (avoid mucous membranes and normal skin); do not occlude; may increase to 3-4 times daily as tolerated. Reduce frequency or suspend treatment if local toxicity occurs. |
| Precautions |
|
Not for use when systemic KS therapy required. Avoid sun, UV light. Flammable. Pregnancy (Cat.D), nursing mothers: not recommended. |
| Interactions |
|
Increases DEET toxicity (avoid). |
| Adverse Reactions |
|
Photosensitivity, rash, pruritus, pain, exfoliative dermatitis, paresthesia, edema. |
| How Supplied |
|
Gel—60g |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
